AnaptysBio, Inc.
(NASDAQ : ANAB)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 10.73%61.500.0%$1907.60m
REGNRegeneron Pharmaceuticals, Inc. 5.98%612.812.5%$1175.40m
GILDGilead Sciences, Inc. 3.33%77.831.0%$1168.63m
AMGNAmgen, Inc. 2.49%229.701.3%$672.54m
VRTXVertex Pharmaceuticals, Inc. 3.81%287.961.9%$606.67m
NVAXNovavax, Inc. 2.68%46.04102.0%$590.02m
BIIBBiogen, Inc. 2.19%307.091.6%$417.42m
ILMNIllumina, Inc. -2.67%363.053.5%$387.48m
SRNESorrento Therapeutics, Inc. 2.02%5.051.8%$306.68m
ALXNAlexion Pharmaceuticals, Inc. 4.79%119.902.0%$292.13m
SGENSeattle Genetics, Inc. 3.74%157.216.1%$269.08m
AAgilent Technologies, Inc. 1.67%88.141.6%$202.48m
BMRNBioMarin Pharmaceutical, Inc. 0.90%106.554.3%$186.35m
CODXCo-Diagnostics, Inc. 3.03%18.000.0%$173.36m
INCYIncyte Corp. 1.35%101.912.5%$166.15m

Company Profile

AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its products pipeline include ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.